search
Back to results

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Primary Purpose

Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Sponsored by
Genzyme, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mucopolysaccharidosis I

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Have a documented diagnosis of MPS I, confirmed by measurable clinical signs and symptoms of MPS I, and a documented fibroblast or leukocyte α-L-iduronidase enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory. Weigh at least 12.5 kg. Have serum creatinine and blood urea nitrogen (BUN) values within age appropriate normal ranges. Provide signed, written informed consent prior to any protocol-related procedures being performed. Consent of a legally authorized guardian(s) is (are) required for patients under 18 years. If the patient is under 18 years old and can understand the consent, written informed consent will be required from both the patient and the authorized guardian(s). Exclusion Criteria: Have previously received Aldurazyme® (laronidase). Have a suspected hypersensitivity to Aldurazyme® (laronidase) or known hypersensitivity to components of the infusion solution. Have previously undergone hematopoietic stem cell transplantation (HSCT; i.e., from bone marrow [BMT], peripheral blood, or umbilical cord blood) or other major organ transplantation. Have a medical condition, serious inter-current illness, or other extenuating circumstance that may interfere with study compliance including all prescribed evaluations and follow-up activities, except the 6MWT. (Note: All patients may not be capable of performing the 6MWT due to age and/or maturity level. Exemption from performing the 6MWT must be obtained in writing by the investigator from the sponsor's medical monitor prior to enrollment). Have an acute illness that requires surgical intervention, and/or anticipates surgery during study participation, and/or has had surgery within 30 days prior to study enrollment. Have received an investigational drug within 30 days prior to study enrollment. Is pregnant or lactating. Female patients of childbearing potential must have a negative pregnancy test [urine β-human chronic gonadotropin (hCG)] at entry (prior to the first infusion). Note: All female patients of childbearing potential and sexually mature males must be advised to use a medically accepted method of contraception throughout the study.

Sites / Locations

  • Hospital Infantil Joana de Gusmao
  • Universidade Federal de Minas Gerais
  • Hospital de Clinical de Porto Alegre
  • Universidade Federal de Sao Paulo
  • Division of Clinical and Metabolic Genetics

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

1

2

3

4

Arm Description

0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.

1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.

1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.

1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.

Outcomes

Primary Outcome Measures

Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Level
Urinary GAG Level - Concentration of GAG relative to creatinine in urine. A greater decrease in GAG level indicates a greater response.

Secondary Outcome Measures

Percent Change From Baseline to Week 26 in Liver Organ Volume
A greater decrease in liver volume indicates a greater response.
Change From Baseline to Week 26 in Six Minute Walk Test (6MWT)
Six Minute Walk Test: Distance walked (measured in Meters) in 6 minutes. A longer distance indicates a greater response.

Full Information

First Posted
September 2, 2005
Last Updated
March 17, 2015
Sponsor
Genzyme, a Sanofi Company
Collaborators
BioMarin/Genzyme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00144781
Brief Title
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
Official Title
A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
December 2004 (undefined)
Primary Completion Date
January 2006 (Actual)
Study Completion Date
January 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Genzyme, a Sanofi Company
Collaborators
BioMarin/Genzyme LLC

4. Oversight

5. Study Description

Brief Summary
The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
Arm Title
2
Arm Type
Active Comparator
Arm Description
1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
Arm Title
3
Arm Type
Active Comparator
Arm Description
1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
Arm Title
4
Arm Type
Active Comparator
Arm Description
1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
Intervention Type
Biological
Intervention Name(s)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Intervention Description
0.58 mg/kg every week
Intervention Type
Biological
Intervention Name(s)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Intervention Description
1.2 mg/kg every week
Intervention Type
Biological
Intervention Name(s)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Intervention Description
1.2 mg/kg every other week
Intervention Type
Biological
Intervention Name(s)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Intervention Description
1.8 mg/kg every other week
Primary Outcome Measure Information:
Title
Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Level
Description
Urinary GAG Level - Concentration of GAG relative to creatinine in urine. A greater decrease in GAG level indicates a greater response.
Time Frame
Baseline to 26 Weeks
Secondary Outcome Measure Information:
Title
Percent Change From Baseline to Week 26 in Liver Organ Volume
Description
A greater decrease in liver volume indicates a greater response.
Time Frame
Baseline to 26 Weeks
Title
Change From Baseline to Week 26 in Six Minute Walk Test (6MWT)
Description
Six Minute Walk Test: Distance walked (measured in Meters) in 6 minutes. A longer distance indicates a greater response.
Time Frame
Baseline to 26 Weeks

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have a documented diagnosis of MPS I, confirmed by measurable clinical signs and symptoms of MPS I, and a documented fibroblast or leukocyte α-L-iduronidase enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory. Weigh at least 12.5 kg. Have serum creatinine and blood urea nitrogen (BUN) values within age appropriate normal ranges. Provide signed, written informed consent prior to any protocol-related procedures being performed. Consent of a legally authorized guardian(s) is (are) required for patients under 18 years. If the patient is under 18 years old and can understand the consent, written informed consent will be required from both the patient and the authorized guardian(s). Exclusion Criteria: Have previously received Aldurazyme® (laronidase). Have a suspected hypersensitivity to Aldurazyme® (laronidase) or known hypersensitivity to components of the infusion solution. Have previously undergone hematopoietic stem cell transplantation (HSCT; i.e., from bone marrow [BMT], peripheral blood, or umbilical cord blood) or other major organ transplantation. Have a medical condition, serious inter-current illness, or other extenuating circumstance that may interfere with study compliance including all prescribed evaluations and follow-up activities, except the 6MWT. (Note: All patients may not be capable of performing the 6MWT due to age and/or maturity level. Exemption from performing the 6MWT must be obtained in writing by the investigator from the sponsor's medical monitor prior to enrollment). Have an acute illness that requires surgical intervention, and/or anticipates surgery during study participation, and/or has had surgery within 30 days prior to study enrollment. Have received an investigational drug within 30 days prior to study enrollment. Is pregnant or lactating. Female patients of childbearing potential must have a negative pregnancy test [urine β-human chronic gonadotropin (hCG)] at entry (prior to the first infusion). Note: All female patients of childbearing potential and sexually mature males must be advised to use a medically accepted method of contraception throughout the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Information
Organizational Affiliation
Genzyme, a Sanofi Company
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Infantil Joana de Gusmao
City
Florianopolis
State/Province
Santa Catarina
ZIP/Postal Code
CEP 88025-601
Country
Brazil
Facility Name
Universidade Federal de Minas Gerais
City
Belo Horizonte
ZIP/Postal Code
CEP 30130-100
Country
Brazil
Facility Name
Hospital de Clinical de Porto Alegre
City
Porto Alegre
ZIP/Postal Code
CEP 90035-003
Country
Brazil
Facility Name
Universidade Federal de Sao Paulo
City
San Paulo
ZIP/Postal Code
CEP 04023-062
Country
Brazil
Facility Name
Division of Clinical and Metabolic Genetics
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

We'll reach out to this number within 24 hrs